Who We Are
Ikaria Australia Pty Ltd is now a part of Mallinckrodt Pharmaceuticals. Mallinckrodt is a global specialty pharmaceutical business that develops, manufactures, markets and distributes specialty pharmaceutical products.
Currently, INOmax® (nitric oxide) for inhalation is Ikaria’s commercialised product in Australia. Ikaria Australia is dedicated to support Australian research due to the company’s strategic vision of being a valued partner in Critical Care. At Ikaria Australia, we look forward to expanding our product portfolio to address the unmet needs of Australian patients and clinicians in the near future.